FDA notifications. FDA grants approval for generic didanosine for oral solution.
D000284:Administration, Oral; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use; D016568:Drugs, Generic; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D018119:Stavudine / Q000008:administration & dosage / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D000099227:Abacavir
D016049:Didanosine; D015224:Dideoxynucleosides; D016568:Drugs, Generic; D061466:Lopinavir; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine; D000099227:Abacavir